CLOs on the Move

Ophthotech

www.ophthotech.com

 
Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Wake Research

Wake Researchs network of high-quality research sites and millions of patients is built on decades of experience meeting the needs of sponsors & CROs.

Pfeiffer Pharmaceuticals

Pfeiffer Pharmaceuticals is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Abacus Medicine A/S

The Abacus Medicine Group creates better access to medicine. We help life-critical medicines become more widely available.

Respira Therapeutics

Respira Therapeutics, Inc., founded in 2010 with offices in Albuquerque, New Mexico, is a development stage inhaled pharmaceutical development company focused on commercializing its "best in class", high efficiency AOS-DPI, dry powder inhaler (DPI) drug delivery technology to deliver RT234, a proprietary inhaled formulation of an off patent oral drug via the lung to treatment of multiple orphan indications in the fields of pulmonary hypertension and other diseases. Investors in Respira include Cottonwood Technology Fund and Sun Mountain Capital and individual investors. To date Respira has performed extensive testing demonstrating its advanced AOS-DPI prototypes can deliver 2-3X more drug to the lung than commercially available DPI technologies. Respira is planning proof of concept clinical trials of an inhaled formulation of RT234 in pulmonary arterial hypertension patients in the near future.

Genvion Corporation

Genvion Corporation is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.